TrialSignal transduction and targeted therapy2025

Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial.

Run-Cong Nie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.